zoladex

Instructions for Goserelin

Common name: Goserelin injection
Trade name: Norred
All names: goserelin, goserelin, goserelin, sexrelin, norred, goserelin Injection, Goserelin acetate sustained-release implant, Goserelin

Indications:
Suitable for hormone therapy for prostate cancer, premenopausal and perimenopausal breast cancer, and endometriosis.

Usage and dosage:
For adults, 3.6 mg of injection implant should be injected subcutaneously into the anterior abdominal wall once every 28 days. Local anesthesia can be used if necessary.
There is no need to adjust the dose in patients with liver or renal insufficiency or elderly patients.
The course of treatment for endometriosis patients is 6 months.

Adverse reactions:
1. Rashes have been reported, mostly mild, and can be recovered without interrupting treatment. Occasional local reactions include mild bruising at the injection site.
2. It has been reported that it can cause changes in blood pressure, but generally does not require treatment.
3. Side effects in male patients include flushing and decreased sexual function, which rarely require interruption of treatment. Occasionally, breast swelling and tenderness may occur. Patients with prostate cancer may experience a temporary increase in bone pain in the early stages of administration, and should be treated symptomatically. Individual cases of urethral obstruction and spinal cord compression have also been reported. LHGH agonists may cause bone loss when used in men.
4. Side effects in female patients include flushing, sweating, and decreased libido, and there is no need to discontinue treatment; headaches, mood changes such as depression, vaginal dryness, and changes in breast size have also been observed. Patients with breast cancer in the early stages of treatment will have aggravation of symptoms and should be treated according to symptoms. A very small number of women with endometriosis experience amenorrhea during treatment with LHRH analogues, and menstruation does not resume after stopping treatment.

Taboos:
Pregnant women and wet nurses are prohibited. Use with caution in male patients with urethral obstruction or spinal cord compression.
Contraindicated for those allergic to any component of this product.

Notes:
Male patients who are prone to urethral obstruction or spinal cord compression should use it with caution, and the patient should be closely monitored during the first month of treatment. If spinal cord compression or renal insufficiency due to urethral obstruction develops and worsens, appropriate treatment should be administered.
The use of luteinizing hormone-releasing hormone agonists in women can cause a decrease in bone mineral density. Existing data show that after 6 months of using this drug, vertebral bone mineral density decreases by an average of 4.6%. Six months after stopping treatment, it can gradually return to an average decrease of 2.6% compared to the baseline.
Women suffering from metabolic bone diseases should use this drug with caution.
There is no clinical data on the use of Norade for more than 6 months in the treatment of endometriosis.

Storage:
Store below 25℃

Mechanism of action:
It is an analogue of luteinizing hormone-releasing hormone. Long-term use of this product can inhibit the pituitary gland from promoting luteinizing hormone. The synthesis of somatogenin causes a decrease in male serum testosterone and female serum estradiol. This effect is reversible after discontinuation of the drug. During initial use, this product can temporarily increase the concentrations of male serum testosterone and female serum estradiol. In male patients, the serum testosterone concentration drops to the castration level around 21 days after the first injection of this drug, and this concentration is maintained during subsequent treatments. This can make most patients' prostate tumors regress and their symptoms improve. In female patients, serum estradiol levels were suppressed around 21 days after the initial dose and remained at postmenopausal levels for every 28 days of subsequent treatment. The half-life of this product is 2 to 4 hours, and the half-life will increase in patients with renal insufficiency.

Safety and efficacy:

To discuss the clinical therapeutic effect of goserelin after endometriosis surgery. 84 patients undergoing endometriosis surgery were selected as the research subjects, and they were evenly divided into control group and treatment group. The control group received conventional drug treatment after surgery; the treatment group received goserelin treatment on the basis of conventional drug treatment after surgery. Results In terms of treatment effect, the effective rate of the treatment group was 95.23%, and the effective rate of the control group was 83.33%. Conclusion The use of goserelin for postoperative treatment of patients with endometriosis can effectively alleviate various clinical symptoms of the patients, and at the same time, corresponding nursing intervention can accelerate the recovery of the patients, which is worthy of clinical promotion and application.